Noe Juvenal Mendoza-Ramírez

Dr. Noe Juvenal Mendoza-Ramírez

Biomedicina Molecular, CINVESTAV, Mexico City, Ciudad de México, Mexico
orcid
Studies focused in development of fusion proteins of SARS Co...

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
JCJulio García Cordero
Julio García Cordero
Noe Juvenal Mendoza-RamírezNoe Juvenal Mendoza-Ramírez
Noe Juvenal Mendoza-Ramírez
DBDavid Andrés Fernández Benavides
David Andrés Fernández Benavides
DRDaniela Roa-Velazquez
Daniela Roa-Velazquez
JFJessica Filisola-Villaseñor
Jessica Filisola-Villaseñor
LCLeticia Cedillo-Barron
Leticia Cedillo-Barron
The coronavirus disease 2019 (COVID-19) pandemic has reached an unprecedented level. There is a strong demand for diagnostic and serological supplies worldwide, making it necessary for countries to establish their own technologies to produce high-quality biomolecules. The two main viral antigens used for the diagnostics for severe acute respiratory syndrome coronavirus (SARS-CoV-2) are the structural proteins spike (S) protein and nucleocapsid (N) protein. The spike protein of SARS-CoV-2 is cleaved into S1 and S2, in which the S1 subunit has the receptor-binding domain (RBD), which induces the production of neutralizing antibodies, whereas nucleocapsid is an ideal target for viral antigen-based detection. In this study, we designed plasmids, pcDNA3.1/S1 and pcDNA3.1/N, and optimized their expression of the recombinant S1 and N proteins from SARS-CoV-2 in a mammalian system. The RBD was used as a control. The antigens were successfully purified from Expi293 cells, with high yields of the S1, N, and RBD proteins. The immunogenic abilities of these proteins were demonstrated in a mouse model. Further, enzyme-linked immunosorbent assays with human serum samples showed that the SARS-CoV-2 antigens are a suitable alternative for serological assays to identify patients infected with COVID-19.

1 January 2024 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
Noe Juvenal Mendoza-RamírezNoe Juvenal Mendoza-Ramírez
Noe Juvenal Mendoza-Ramírez
JCJulio García Cordero
Julio García Cordero
Gaurav ShrivastavaGaurav Shrivastava
Gaurav Shrivastava
LCLeticia Cedillo-Barron
Leticia Cedillo-Barron
Vaccination is one of the most effective prophylactic public health interventions for the prevention of infectious diseases such as coronavirus disease (COVID‐19). Considering the ongoing need for new COVID‐19 vaccines, it is crucial to modify our approach and incorporate more conserved regions of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) to effectively address emerging viral variants. The nucleocapsid protein is a structural protein of SARS‐CoV‐2 that is involved in replication and immune responses. Furthermore, this protein offers significant advantages owing to the minimal accumulation of mutations over time and the inclusion of key T‐cell epitopes critical for SARS‐CoV‐2 immunity. A novel strategy that may be suitable for the new generation of vaccines against COVID‐19 is to use a combination of antigens, including the spike and nucleocapsid proteins, to elicit robust humoral and potent cellular immune responses, along with long‐lasting immunity. The strategic use of multiple antigens aims to enhance vaccine efficacy and broaden protection against viruses, including their variants. The immune response against the nucleocapsid protein from other coronavirus is long‐lasting, and it can persist up to 11 years post‐infection. Thus, the incorporation of nucleocapsids (N) into vaccine design adds an important dimension to vaccination efforts and holds promise for bolstering the ability to combat COVID‐19 effectively. In this review, we summarize the preclinical studies that evaluated the use of the nucleocapsid protein as antigen. This study discusses the use of nucleocapsid alone and its combination with spike protein or other proteins of SARS‐CoV‐2.

18 April 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
Noe Juvenal Mendoza-RamírezNoe Juvenal Mendoza-Ramírez
Noe Juvenal Mendoza-Ramírez
JCJulio García Cordero
Julio García Cordero
SMSandra Paola Martínez-Frías
Sandra Paola Martínez-Frías
DRDaniela Roa-Velázquez
Daniela Roa-Velázquez
RLRosendo Luria-Pérez
Rosendo Luria-Pérez
LCLeticia Cedillo-Barron
Leticia Cedillo-Barron
Despite all successful efforts to develop a COVID-19 vaccine, the need to evaluate alternative antigens to produce next-generation vaccines is imperative to target emerging variants. Thus, the second generation of COVID-19 vaccines employ more than one antigen from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to induce an effective and lasting immune response. Here, we analyzed the combination of two SARS-CoV-2 viral antigens that could elicit a more durable immune response in both T- and B-cells. The nucleocapsid (N) protein, Spike protein S1 domain, and receptor binding domain (RBD) of the SARS-CoV-2 spike surface glycoproteins were expressed and purified in a mammalian expression system, taking into consideration the posttranscriptional modifications and structural characteristics. The immunogenicity of these combined proteins was evaluated in a murine model. Immunization combining S1 or RBD with the N protein induced higher levels of IgG antibodies, increased the percentage of neutralization, and elevated the production of cytokines TNF-α, IFN-γ, and IL-2 compared to the administration of a single antigen. Furthermore, sera from immunized mice recognized alpha and beta variants of SARS-CoV-2, which supports ongoing clinical results on partial protection in vaccinated populations, despite mutations. This study identifies potential antigens for second-generation COVID-19 vaccines.

23 September 2025 in Advanced NanoBiomed Research
Verified
Journal Article
Open access
Noe Juvenal Mendoza-RamírezNoe Juvenal Mendoza-Ramírez
Noe Juvenal Mendoza-Ramírez
JCJulio García Cordero
Julio García Cordero
GNGabriela Navarro-Tovar
Gabriela Navarro-Tovar
LCLeticia Cedillo-Barron
Leticia Cedillo-Barron
Silica microparticles and nanoparticles (SiNPs) have been studied as vehicles for vaccines. They are safe, biodegradable, and biocompatible and can be used as carriers and adjuvants. These particles are applied in both noncommunicable and infectious disease research for new treatments to address priority health challenges. Several reviews report the use of SiNPs in cancer vaccines. The aim of this review is to provide a detailed summary of the use of SiNPs in vaccines against infectious diseases over the last 12 years. The use of silica particles in classical vaccines based on recombinant subunits or whole proteins and in recent vaccines based on nucleic acids, such as DNA and mRNA, is discussed. Additionally, the intrinsic properties of the particles that induce an immune response and their use as adjuvants are outlined. Easy modification of the surface of silica particles facilitates their interaction with different molecules, such as DNA or RNA, making these particles good vehicles. Additionally, preclinical studies on vaccines against human infections and animal diseases are discussed.

28 January 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
Noe Juvenal Mendoza-RamírezNoe Juvenal Mendoza-Ramírez
Noe Juvenal Mendoza-Ramírez
JCJulio García Cordero
Julio García Cordero
Gabriela Hernández-GaliciaGabriela Hernández-Galicia
Gabriela Hernández-Galicia
NMNicole Justine Moreno-Licona
Nicole Justine Moreno-Licona
Jesús HernándezJesús Hernández
Jesús Hernández
LCLeticia Cedillo-Barron
Leticia Cedillo-Barron
Background: Next-generation vaccines against coronavirus disease 2019 (COVID-19) focus on inducing a long-lasting immune response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its emerging variants. To achieve this, antigens other than spike proteins have been proposed, and different platforms have been evaluated. Nucleic acid-based vaccines are fundamental for this process. Preclinical data have shown that the SARS-CoV-2 nucleocapsid protein induces a protective cellular immune response, and when combined with the spike protein, the resulting humoral and cellular immune responses are effective against some SARS-CoV-2 variants. Methods: We designed a DNA vaccine against the spike and nucleocapsid proteins of SARS-CoV-2 to generate fusion proteins based on the Delta and Omicron B.5 strains. The most immunogenic regions of the spike and nucleocapsid proteins of the Delta and Omicron B strains were selected using bioinformatics. The nucleotide sequences were cloned into pcDNA3.1, and named pcDNA3.1/D-S1, pcDNA3.1/D-S1N, and pcDNA3.1/O-SN. The immunogenicity of the generated fusion proteins was evaluated by analyzing the humoral and cellular responses elicited after the immunization of BALB/c mice. Results: DNA immunization induced antibody production, neutralization activity, and IFN-γ production. The inclusion of the nucleocapsid regions in the plasmid greatly enhanced the immune response. Moreover, cross-reactions with the variants of interest were confirmed. Conclusions: Plasmids-encoding fusion proteins combining the most immunogenic regions of the spike and nucleocapsid proteins present a promising strategy for designing new and effective vaccines against SARS-CoV-2.

10 July 2026 in Protein Expression and Purification
Verified
Journal Article
Open access
DRDaniela Roa-Velázquez
Daniela Roa-Velázquez
JFJessica Georgina Filisola-Villaseñor
Jessica Georgina Filisola-Villaseñor
DZDan Israel Zavala
Dan Israel Zavala
JCJulio García Cordero
Julio García Cordero
Noe Juvenal Mendoza-RamírezNoe Juvenal Mendoza-Ramírez
Noe Juvenal Mendoza-Ramírez
EMEdgar Morales-Ríos
Edgar Morales-Ríos
The receptor-binding domain (RBD) of SARS-CoV-2 spike glycoprotein is central to serological diagnostics and vaccine development, but production in eukaryotic expression systems is costly and technically demanding. Here, we describe an Escherichia coli platform to express the wild-type RBD, used as an initial model for the standardization of the methodology. Subsequently, the platform was applied to the alpha and beta variants, demonstrating its adaptability to different RBD variants. Inclusion bodies were purified under denaturing conditions and refolded by size-exclusion chromatography using a linear urea gradient and a redox/anti-aggregation buffer that promotes correct disulfide-bond formation and minimizes aggregation. The procedure yielded ∼36 mg of soluble protein per liter of culture. The refolded recombinant RBDs of wild-type, alpha and beta variants, as well as RDB wild-type produced in Expi293 cells as a control were evaluated in ELISA assays against sera from healthy, vaccinated and convalescent SARS-CoV-2 patients. All recombinant RBDs produced in E. coli were recognized by patients' sera, demonstrating that they retain antigenicity and supporting their use in serological assays as a rapid and scalable source of antigens.